Andrew In

Andrew In is an experienced formulation scientist currently employed at Halo Pharmaceutical, Inc. since August 2022, where responsibilities include leading IR formulation projects, creating and executing batch records, and optimizing formulations using risk assessments and Quality by Design (QbD) principles. Prior roles include serving as Associate Scientist and Formulation Chemist at Alvogen since February 2017, where Andrew In demonstrated expertise in various manufacturing equipment and effective communication with project teams. Previous experience encompasses positions at Catalent Pharma Solutions and AustarPharma, LLC, focusing on cGMP manufacturing, root cause analysis, and laboratory analysis techniques such as UV and HPLC. Andrew In holds a Master of Engineering in Pharmaceutical Sciences from Rutgers University and a Bachelor's degree in Chemical Engineering from the University at Buffalo.